Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag™

Source : 

Biotinylated Human LILRB1, Fc,Avitag (CDJ-H82F7) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - His 458 (Accession # D9IDM8-1).

 

Molecule : LILRB1

 

Synonyms : CD85J,LILRB1,CD85,ILT2,LIR1,MIR7

 

Format : Powder

 

Category : MABSol® Biotin Labeled Proteins

 

Accession : AAH15731.1

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 75.6 kDa

 

Characteristics :

This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™). The protein has a calculated MW of 75.6 kDa. As a result of glycosylation, the protein migrates as 100-116 kDa under reducing (R) condition, and 150 kDa under non

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : Tris with Glycine, Arginine and NaCl, pH7.5

 

Description :

CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

 

References :

(1) Cosman D., et al., 1997, Immunity 7:273-282.
(2) Fanger N.A., et al., 1998, Eur. J. Immunol. 28:3423-3434.
(3) Chapman T.L., et al., 1999, Immunity 11:603-613.
(4) Bellon T., et al., 2002, J. Immunol. 168:3351-3359.